Table 2 |
|||||||
|
KRAS and treatment response to Cetuximab-containing regiments in chemotherapy-naïve patients with colorectal carcinoma. |
|||||||
|
Study |
Treatments |
KRAS |
N (%) |
RR, N (%) |
TTP (months) |
OS (months) |
Remarks |
|
|
|||||||
|
Bokemeyer, 2008 |
FOLFOX + CTX |
WT |
61 |
37 (60.7%) |
7.7 |
NA |
KRAS MT has worse RR and TTP. Cetuximab may have detrimental effects in KRAS MT. |
|
MT |
52 (46.0%) |
17 (32.7%) |
5.5 |
NA |
|||
|
FOLFOX |
WT |
73 |
27 (37.0%) |
7.2 |
NA |
||
|
MT |
47 (39.2%) |
23 (48.9%) |
8.6 |
NA |
|||
|
Cervantes, 2008 |
CTX |
WT |
29 |
8 (27.6%) |
NA |
NA |
Patients were treated with CTX first, then in combination with chemo. KRAS MT has worse RR and TTP. |
|
MT |
19 (39.6%) |
0 |
NA |
NA |
|||
|
CTX + FOLFIRI |
WT |
29 |
16 (55.2%) |
9.4 |
NA |
||
|
MT |
19 (39.6%) |
6 (31.6%) |
5.6 |
NA |
|||
|
Punt, 2008 |
CapOxBev+CTX |
WT |
153 |
NA |
10.5 |
22.2 |
KRAS MT has worse TTP, and OS. Cetuximab may have detrimental effects in KRAS MT. |
|
MT |
93 (37.8%) |
NA |
8.6 |
19.1 |
|||
|
CapOxBev |
WT |
152 |
NA |
10.7 |
23.0 |
||
|
MT |
103 (40.4%) |
NA |
12.5 |
24.9 |
|||
|
Van Custem, 2008 |
FOLFIRI + CTX |
WT |
172 |
102 (59.3%) |
9.9 |
NA |
KRAS MT has worse RR and TTP. Cetuximab may have detrimental effects in KRAS MT. |
|
MT |
105 (37.9%) |
38 (36.2%) |
7.6 |
NA |
|||
|
FOLFIRI |
WT |
176 |
76 (43.2%) |
8.7 |
NA |
||
|
MT |
87 (33.1%) |
35 (40.2%) |
8.1 |
NA |
|||
|
|
|||||||
|
Abbreviations: CTX = cetuximab; PAN = panitumumab; IRI = irinotecan; Ox = oxaliplatin; Cap = capcitabine; Bev = bevacizumab; BSC = best supportive care; WT = wild type; MT = mutant type; NA = Not Available or Not Applicable; RR = objective response rate (complete response + partial response); TTP = time to progression; OS = overall survival. |
|||||||
|
Chang et al. Journal of Hematology & Oncology 2009 2:18 doi:10.1186/1756-8722-2-18 |
|||||||
